Tumgik
#therapeutics
nietzschesbible · 2 years
Text
Tom The Rapist
At a cross roads, on a bridge
I met you there
I hung my feet, like hanged men’s dance
Another chance?
A true romance?
Or just another witsful glance...
Into a future, fated
I gave you my trust
From gawking screens
To silent screams
Bare-faced touch
You know too much
The dream, it’s faded
Our past too jaded
You touched me as he did
Behind you lays in wake a death
Strangled love on bated breath
I danced for you my hanged man’s dance
From look to book
From past to farce
From now to then
We’ll start again
Just not as friends
I met you there
I’ll leave you here.
Hanged men trip the light fantastic
But only for a while
75 notes · View notes
umirr79jf · 1 year
Text
Poonam Pandey Nude Compliation Sunny Leone Mia khalifa ava addams lena paul August ames Mia malkova angela White jhonny Jonnysins karlie grey brandi love jessa rhodes Brother fucks sister while friend is watching Straight filipino fucking mexican gay The Legendary Bait Bus White girl with perfect ass Fucking Sexy Big Booty Stripper my best friend helps me to fuck my step dad Moti thick curvy aunty from lahore pakistan cam show Loquita de Panama Riley Reid dando a buceta e tomando porra
1 note · View note
pressnewsagencyllc · 6 days
Text
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics, Inc. ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…
Tumblr media
View On WordPress
1 note · View note
helthcareheven · 10 days
Text
Guardians of Global Health: Innovators in Infectious Disease Therapeutics.
Introduction to Infectious Diseases
Infectious diseases have plagued humanity for millennia. Caused by pathogenic microorganisms like bacteria, viruses, parasites or fungi, these diseases can range from mild illnesses to life-threatening ones. Some of the major infectious diseases that have devastated populations include smallpox, tuberculosis, malaria, influenza and AIDS. Even today, infectious diseases remain one of the leading causes of death globally. According to the World Health Organization, infectious diseases account for around 17 million deaths annually worldwide. Addressing infectious diseases has been an ongoing medical challenge. This article discusses some of the approaches and therapeutic developments being made in the area of infectious disease therapeutics.
Antibacterial Drug Development
One of the main approaches to combating infectious diseases is through the development of antibacterial and antiviral drugs. For bacterial infections, scientists have long relied on antibiotics. However, with the rise of antibiotic-resistant bacteria, we are facing a growing crisis of ineffective antibiotics. Several pathogens like methicillin-resistant Staphylococcus aureus (MRSA) and a host of new "superbugs" have evolved resistance to frontline antibiotics. This has spurred renewed efforts in antibacterial drug research and development. Several pharmaceutical companies and research institutes are working on new classes of antibiotics with novel mechanisms of action to overcome existing resistance problems. Some of the new classes of antibacterials in clinical trials include antibiotics targeting bacterial respiration, cell wall synthesis and RNA processing. Other innovative platforms for antibacterial drug delivery include using bacteriophages to deliver anti-bacterial payloads directly into bacterial cells.
Antiviral Drug Development
For viral diseases, development of effective antiviral drugs is another key approach followed. However, designing antivirals poses unique challenges due to viruses' ability to rapidly mutate and evolve resistance. Currently, antivirals are available for some common viral illnesses such as influenza, hepatitis, herpes and HIV. But new antiviral targets and platforms are being explored for other emerging and re-emerging viral diseases. Some of the new classes of antivirals in development target mechanisms like viral entry, replication, assembly and egress. Other innovative anti-viral drug platforms harness RNA interference and gene editing tools like CRISPR. Monoclonal antibody therapies are also emerging as potent antiviral strategies. Even for diseases with existing antivirals like HIV, new long-acting drugs and gene/immunotherapy based functional cures are being pursued to achieve long-term remission without lifelong drug regimens.
Vaccines for Prevention
Historically, vaccines have proved hugely successful in preventing infectious diseases on a population scale. For instance, global eradication of smallpox was achieved via the smallpox vaccination program. Today, newer vaccine technologies are being leveraged to develop preventives against several infectious agents. Some of these technologies are nucleic acid (DNA/RNA) based vaccines, subunit vaccines, virus-like particle vaccines and recombinant vector vaccines (using viral vectors). Apart from vaccines against classic diseases like flu, pertussis and pneumococcus; candidates are also in development for infections like tuberculosis, malaria, Zika and Ebola. Researchers are also working on pan-influenza, pan-coronavirus and pan-serotype vaccines with broad protection. With vaccine research leveraging advances in immunology, genomics and bioengineering – hopes are high that many more diseases can be controlled or eliminated through vaccination in the future.
Role of Diagnostics
Rapid and accurate diagnostics also play an important support role in infectious disease management. Traditional diagnostic methods are being supplemented by new technologies like isothermal nucleic acid amplification platforms, biosensors, lab-on-chip systems and molecular diagnostics. For example, POC molecular tests like loop mediated isothermal amplification (LAMP) provide gene-detection in less than an hour without sophisticated labs. Diagnostic tools based on CRISPR and nanopore sequencers can achieve real-time sequencing and detection. Whole genome sequencing is also finding applications in tracking disease transmission, carrying out surveillance of pathogens and facilitating timely public health responses. Going forward, multiplexed diagnostics that can simultaneously detect and identify a panel of pathogens from a single patient sample will become more common. This will aid prompt treatment decisions.
Conclusion
In summary, a multi-pronged approach involving preventive as well as curative interventions like vaccines, antibiotics, antivirals and rapid diagnostics is essential to address the persisting threat of infectious diseases. With cutting-edge technologies and innovative drug-delivery platforms being leveraged, there is optimism that novel therapeutics and diagnostics will continue to be developed for both prevalent as well as emerging infectious agents. While resistant pathogens remain a challenge, continued focus on R&D for infectious disease therapeutics hold promise to control infections more effectively in the future.
0 notes
ryandjaxon · 2 months
Text
Love is nonlinear. Life’s core is quantum.
Ryan Douglas Jackson, Flex
0 notes
Photo
Tumblr media
Digital Therapeutics Market Size, Overview, Growth, Demand and Forecast to 2031 
The Digital Therapeutics Market has achieved remarkable success, boasting a valuation of $4.69 billion in 2022, and is poised for exponential growth with a projected Compound Annual Growth Rate (CAGR) of 25.7% over the forecast period. This unprecedented expansion is driven by several key factors that underscore the transformative impact of digital therapeutics on modern healthcare. A paramount catalyst for the burgeoning digital therapeutics market is the escalating prevalence of chronic diseases, including diabetes, hypertension, and mental health conditions. The pressing need for innovative, cost-effective treatment solutions has paved the way for digital therapeutics to emerge as a game-changer, offering personalized interventions that revolutionize patient care. The ubiquity of smartphones and wearable devices has played a pivotal role in shaping the landscape of digital therapeutics. These technologies not only enhance patient engagement but also facilitate robust data collection, laying the foundation for the development of cutting-edge, data-driven therapeutic interventions. The intersection of technology and healthcare has never been more profound, enabling a new era of tailored treatment plans that cater to individual patient needs.
0 notes
pharmanucleus1 · 3 months
Text
Global Nuclear Medicine Therapeutics Market: Pioneering Healthcare Solutions
A pharmaceutical composition including radioactive elements is known as therapeutic nuclear medicine. In comparison to X-rays and other external radiation imaging technologies, therapeutic nuclear medicines are widely employed as an effective and safer alternative for cancer patients. 
Market Size & Growth Rate:                                                                                                            
The nuclear medicine therapeutics market was valued at USD 1 billion in 2021 and is expected to reach USD 1.8 billion by 2027, exhibiting a CAGR of 9.6% during the forecast period 2022-2027. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies. 
Market Dynamics:                                                                                                                              
According to the oncidium foundation, nuclear-therapy accounted for 20% of the global nuclear medicine market in 2019 and is expected to reach 70% by 2030. Nuclear therapeutic is majorly used for the treatment & diagnosis of Cardiovascular Disease (CVD) and cancers. According to WHO-2021, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. The prevalence of these markets has promoted several market players and stakeholders to focus on expanding the overall application of radio-therapeutics. With the expanding application segments of nucleo-emitters, their demand and anticipated rising during the forecast period. It indicates to market players for growth of the nuclear medicine therapeutics market. In addition, various R&D activities in the business space are expected to stimulate the demand for therapeutic nuclear medicine through 2029. For instance, 
Click here for full report:
https://www.pharmanucleus.com/reports/nuclear-medicine-therapeutics
Click here for Free Sample:
https://www.pharmanucleus.com/request-sample/1165
Based on the radionuclide therapeutic type, the beta emitters segment grow at a considerable pace during the forecast period. These beta particles like Samarium-153 (SM-153), Iodine-131 (I-131), and Lutetium-177 (LU-177) are known to be lighter than alpha particles like Radium-224 (RA-224), Radium-223 (RA-223) and can penetrate the skin easily                                     
Get more details on this report - Request Free Sample
According to precedence research, by application, the oncology segment accounted major market share of around 40% in 2021 followed by cardiology. 
Market Drivers:
Click here for full report:
https://www.pharmanucleus.com/reports/nuclear-medicine-therapeutics
The market players are focusing on various research developments, product launches, and acquisitions that are anticipated to increase the market growth. For instance, 
Challenges:
0 notes
limlibrary · 4 months
Text
Test Bank Therapeutics Evidence-Based Practice for Infusion Therapy 7th edition
Tumblr media Tumblr media
Test Bank Therapeutics Evidence-Based Practice for Infusion Therapy 7th edition
Tumblr media
use promo code EXAM07
0 notes
root-analysis · 5 months
Text
Tumblr media
CAGR Projections & Market Analysis for Digital Therapeutics | 2035  
The global digital therapeutics market CAGR report, a category of the digital health market, is anticipated to grow at a CAGR of 20% and is expected to be worth around USD 20 billion by 2035. The roots analysis features an extensive study of the current landscape, market size, and future opportunities, offering an informed opinion on the likely adoption of digital therapeutic solutions in the healthcare industry.
0 notes
factsnews1 · 5 months
Text
0 notes
imarcunofficial · 6 months
Text
The global anti-tuberculosis therapeutics market size reached US$ 1,354.79 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,991.34 Million by 2028, exhibiting a growth rate (CAGR) of 6.70% during 2023-2028.
1 note · View note
Text
Tumblr media
𝐆𝐞𝐧𝐨𝐦𝐞 𝐄𝐝𝐢𝐭𝐢𝐧𝐠 𝐚𝐧𝐝 𝐂𝐑𝐈𝐒𝐏𝐑 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲: The development of the CRISPR-Cas9 system has revolutionized #geneticengineering and gene editing. Researchers are using this technology to modify genes in organisms
𝐒𝐲𝐧𝐭𝐡𝐞𝐭𝐢𝐜 𝐁𝐢𝐨𝐥𝐨𝐠𝐲: #syntheticbiology involves designing and constructing biological systems or organisms with novel functions or capabilities. This field has led to the creation of synthetic microbes for various applications
Visit @ https://symbiosisonlinepublishing.com/biotechnology/
0 notes
pragmareports · 7 months
Text
1 note · View note
market-insider · 7 months
Text
Biomarkers in Personalized Medicine: A Comprehensive Market Study
The global personalized medicine biomarkers market size is expected to reach USD 43.07 billion by 2030. The growth is attributed to the rising awareness, importance of predicting prognosis, and selection of dose. Moreover, personalized medicine biomarkers serve as an essential tool for the selection of patients and providing the right treatment to the right patient further propelling the demand for personalized medicine biomarkers.
Gain deeper insights on the market and receive your free copy with TOC now @: Personalized Medicine Biomarkers Market Report
Biomarkers are unique analytes that can be utilized to improve diagnosis forecast treatment outcomes and direct treatment decisions. They are crucial to personalized medicine. The increased usage of biomarkers to enhance patient outcomes is popular in clinical trials, and its use in clinical practice is expanding quickly. The development of personalized medicines using biomarkers is expected to create effective and safe therapies for every patient. This is a major relief for patients at advanced stages of chronic diseases like cancer, which further drives the market growth. For instance, in August 2022, VENTANA MMR RxDx Panel, an FDA approved first IHC-based assay used for the identification of patients with advanced cancer that is Pembrolizumab treatment eligible.
Early detection/screening biomarkers predict the outcome of disease in patient population prior to therapy. It can also help enrich clinical trials by helping choose patients more likely to respond to treatment. For instance, Oncotype Dx is a diagnostic test developed by Genomic Health, Inc. This test examines 21 genes and helps predict the likelihood of reoccurrence of breast cancer in a patient after initial treatment. In April 2022, updated ASCO guidelines recommended the usage of the Oncotype DX test for breast cancer patients at early stages to guide treatment decisions.
Moreover, biomarkers are used for their predictive and prognostic utility that helps predict the occurrence of a health condition. For instance, the prostate-specific antigen is used to predict the survival of patients with prostate cancer. CRP is used to predict disease-free survival in breast cancer and as a risk factor in cardiovascular disorders. Serum LDH helps predict survival in case of metastatic brain tumors. Similarly, CA125 helps predict metastatic diseases in patients with uterine carcinoma.
Furthermore, key players operating in the personalized medicine biomarkers industry are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in October 2021, Agilent Technologies Inc. received FDA approval for Agilent Ki-67 IHC MIB-1 pharmDx (Dako Omnis), for the identification of patients with a high risk of breast cancer recurrence.
0 notes
pouletpourri · 6 months
Text
Tumblr media Tumblr media
I know the circustances didn't make it avaliable, but..I kinda wish we had a farewell scene
9K notes · View notes